Oculis Holding AG (OCS) Form 6-K — Jun 25, 2026
Oculis Holding AG filed an updated corporate presentation highlighting positive Phase 2 ACUITY trial results for Privosegtor in optic neuritis. Data showed statistically significant improvements in visual function, including an 18-letter gain in low-contrast visual acuity at month six, alongside significant preservation of retinal layers. The company affirmed a robust balance sheet with no debt and a cash runway extending into the second half of 2029, excluding a 100 million Swiss franc loan facility. Oculis emphasized the strong safety profile of Privosegtor, with no adverse events leading to drug withdrawal or study discontinuation.
Key figures
- Cash Runway
- 2H 2029
- Loan Facility
- CHF100m
- Market Potential Usd
- >$7B
- Pioneer1 enrollment
- ~210
- Predict1 enrollment
- ~160
- Phase2 gcpl improvement m6
- +43%
- Phase2 lcva improvement m6
- +18 ETDRS Letters
- Phase2 rnfl improvement m6
- +30%
- Phase2 neurofilaments reduction m6
- -47%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.